{"entity":{"id":"nct04230109","kind":"trial","name":"Sacituzumab Govitecan In TNBC","aka":["NeoSTAR"],"tldr":"A phase 2 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer, run by Massachusetts General Hospital, now recruiting.","summary":"Sacituzumab Govitecan In TNBC. ClinicalTrials.gov record last updated 2026-07-17: recruiting. Enrollment is planned at 239 participants. Primary completion is estimated at 2028-10. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab Govitecan, Pembrolizumab. Registered primary measures: Pathological complete response(pCR) rate with sacituzumab govitecan.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT04230109","url":"https://clinicaltrials.gov/study/NCT04230109"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["adc","checkpoint-inhibitor"],"targets":["trop2"],"drugs":["sacituzumab-govitecan","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-07-17: recruiting. Enrollment is planned at 239 participants. Primary completion is estimated at 2028-10. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT04230109","phase":"2","setting":"Sacituzumab Govitecan In TNBC","sponsor":"Massachusetts General Hospital","participation":[{"nct":"NCT04230109","source":"https://clinicaltrials.gov/study/NCT04230109","fetchedAt":"2026-10-07T16:53:16.796Z","studySha256":"7242e03f5e2381771b22854ca958b078e22c07a11f1af6a86696ac96fce4e41b","overallStatus":"RECRUITING","lastUpdatePosted":"2026-07-17","leadSponsor":"Massachusetts General Hospital","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":239,"enrolmentType":"ESTIMATED","siteCount":5,"recruitingSiteCount":4,"countries":["United States"]}],"started":"2020-07-14","startedType":"actual","enrolled":239,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04230109/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}